Infant Bacterial Therapeutics

Premature infants are the most vulnerable humans on the planet and for them to survive, grow and thrive they need intensive and specialized care.

Although advances in medical care and handling over the last 30 years have improved survival and well-being of these sensitive infants, both in the immediate post-natal period and in their subsequent lives, current drugs and therapies are mostly designed for adults and are not adapted to this specific, divergent and vulnerable patient population.

Infant Bacterial Therapeutics AB (“IBT”) is a pharmaceutical company based in Stockholm that develops drugs that meets the needs of the premature infant. IBT’s current focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis, a fatal disease that affects premature infants.

Kategorier: Biotech, Pharma

Gå till Infant Bacterial Therapeuticss hemsida